4T Score Calculator for Heparin-Induced Thrombocytopenia (HIT)
The 4T score is the most widely used clinical prediction tool for estimating the pre-test probability of heparin-induced thrombocytopenia (HIT) before lab confirmation. Enter the four criteria below and the calculator returns a total score (0-8), the corresponding risk category (low, intermediate, or high), the approximate pre-test probability of true HIT, and a plain-English interpretation with next-step guidance.
What is HIT and why does the 4T score matter?
Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug reaction that occurs in roughly 0.1-5% of patients receiving heparin, depending on the type of heparin and patient population. The body produces IgG antibodies against platelet factor 4 (PF4) complexed with heparin, which activate platelets and generate a hypercoagulable state. Despite the name, the most dangerous consequence of HIT is not bleeding from a low platelet count but paradoxical thrombosis: DVT, pulmonary embolism, arterial occlusion, and limb ischemia. Without treatment, up to half of HIT patients develop a thromboembolic complication. Early, accurate identification is therefore life-saving. The 4T score was introduced to give clinicians a structured, reproducible way to estimate pre-test probability before laboratory results are available, so that heparin can be stopped promptly in high-risk patients while avoiding unnecessary anticoagulation switches in low-risk ones.
How to use the 4T score in clinical practice
Start by establishing the patient's baseline platelet count before heparin began, and count Day 0 as the first day of heparin exposure. Evaluate each of the four criteria objectively. A low score (0-3) has a negative predictive value above 99% in most studies, meaning HIT is extremely unlikely and heparin can usually continue without antibody testing. An intermediate score (4-5) warrants stopping heparin, switching to a non-heparin anticoagulant such as argatroban, bivalirudin, or fondaparinux, and sending a HIT ELISA. A high score (6-8) should prompt immediate heparin cessation and empiric treatment with a non-heparin anticoagulant pending confirmatory functional testing (serotonin release assay or HIPA test). Importantly, low-molecular-weight heparin should not be substituted for unfractionated heparin in HIT: cross-reactivity approaches 90%. Warfarin should also be avoided until platelets recover, as it can trigger venous limb gangrene in active HIT.
Understanding the four criteria
Thrombocytopenia: Use the platelet count that is lowest after heparin started. A fall of more than 50% to a nadir of at least 20x10⁹/L is the classic HIT pattern and scores 2 points. Smaller falls or nadirs below 10x10⁹/L are unusual for HIT and score 0. Timing: Immune-mediated HIT typically causes platelet fall on days 5-10 of a first heparin course, because it takes 5-10 days to generate the pathogenic antibody. If the patient received heparin within the past 100 days, circulating antibodies can cause a rapid-onset fall on day 1. Onsets after day 10 or within 4 days of first-ever heparin exposure score lower. Thrombosis: New arterial or venous clots, heparin-injection-site skin necrosis, and the dramatic acute systemic reaction (flushing, hypotension, tachycardia) that can follow an IV heparin bolus all point to active HIT and score 2 points. Other causes: Thrombocytopenia in the ICU often has non-HIT explanations, including sepsis, post-cardiac surgery consumption, and other drugs. Identifying a plausible alternative lowers the score.
Limitations and when to use additional tools
The 4T score performs well as a rule-out tool (low scores reliably exclude HIT) but is less reliable for rule-in: up to 25% of patients with a high 4T score do not have confirmed HIT. Interobserver variability is a known limitation, particularly for the timing criterion. The HIT Expert Probability (HEP) score uses nine criteria and shows better interobserver agreement in some studies. For patients with an intermediate or high 4T score, laboratory confirmation is mandatory. A positive PF4-heparin ELISA with an optical density above 1.0 greatly increases the probability of HIT; a confirmatory functional assay (serotonin release assay or heparin-induced platelet activation test) remains the gold standard. Clinical management should integrate the 4T score, antibody testing, and the complete clinical picture.
4T Score criteria and point values
| Criterion | 2 points | 1 point | 0 points |
|---|---|---|---|
| Thrombocytopenia | Fall >50% AND nadir >=20 x10⁹/L | Fall 30-50% OR nadir 10-19.9 x10⁹/L | Fall <30% OR nadir <10 x10⁹/L |
| Timing of fall | Clear onset days 5-10 OR rapid onset with prior heparin 5-30 days ago | Consistent days 5-10 (unclear); onset >10 days; or rapid onset with prior heparin 31-100 days ago | Fall <4 days without recent heparin |
| Thrombosis or sequelae | New confirmed thrombosis, skin necrosis, acute systemic reaction post-IV bolus | Progressive/recurrent thrombosis, non-necrotizing skin lesions, suspected thrombosis | None |
| Other causes | None apparent | Possible other cause | Definite other cause |
Each of the four criteria contributes 0, 1, or 2 points. The maximum possible score is 8.
Frequently asked questions
What is a 4T score and what does it measure?
The 4T score is a validated clinical prediction rule that estimates the pre-test probability of heparin-induced thrombocytopenia (HIT) before confirmatory laboratory tests are available. It assigns 0, 1, or 2 points to each of four criteria: the degree of thrombocytopenia, the timing of the platelet count fall relative to heparin exposure, the presence of thrombosis or other HIT sequelae, and the likelihood that another cause explains the thrombocytopenia. Scores of 0-3 indicate low probability, 4-5 intermediate, and 6-8 high probability.
What should I do for a low 4T score?
A low score (0-3) carries a pre-test probability of roughly 1% and has a very high negative predictive value. Current guidelines from the American Society of Hematology suggest that HIT antibody testing is not necessary and heparin can be continued if otherwise clinically appropriate. You should, however, re-evaluate the score if the platelet count falls further or a new thrombosis develops.
What should I do for an intermediate or high 4T score?
For intermediate (4-5) or high (6-8) scores, heparin should be discontinued immediately and replaced with a non-heparin anticoagulant such as argatroban, bivalirudin, or fondaparinux. A HIT antibody ELISA should be ordered urgently. If the ELISA is strongly positive (optical density >1.0), begin treatment-dose anticoagulation and confirm with a functional assay. Avoid low-molecular-weight heparin (90% cross-reactivity with HIT antibodies) and avoid warfarin until platelets have recovered to reduce the risk of warfarin-associated skin necrosis.
Which day does the timing criterion use as Day 0?
Day 0 is the first day the patient received heparin in the current course. Platelet monitoring begins from Day 0. In a typical new exposure, the immune response builds over 5-10 days before causing platelet activation, so a clear fall on days 5-10 scores the maximum 2 points. If the patient received heparin within the past 30-100 days, pre-formed antibodies can cause a rapid fall on Day 1 or 2, which also scores 2 or 1 point depending on the precise prior-exposure interval.
Can HIT occur with low-molecular-weight heparin?
Yes. HIT can occur with both unfractionated heparin and low-molecular-weight heparin (LMWH), though it is more common with unfractionated heparin. Crucially, in a patient with confirmed or highly suspected HIT, switching to LMWH is not an acceptable alternative because HIT antibodies cross-react with LMWH in approximately 90% of cases. A true non-heparin anticoagulant must be used.
What is the negative predictive value of a low 4T score?
Multiple prospective studies and a 2012 meta-analysis by Cuker et al. found the negative predictive value of a low 4T score (0-3) to be approximately 99.8%, meaning that HIT is extremely unlikely when the score is low. This high NPV is why a low 4T score is considered sufficient to safely rule out HIT without antibody testing in most clinical settings.
Sources
- Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006.
- Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2012.
- American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.